Havana, 9 sep (EFE).-A Cuban vaccine against advanced lung cancer “considerably” improves the State of serious patients and allows the disease to become “controllable Chronicle”, reported today media officers.
The drug has been developed after 15 years of research by scientists at the center of Molecular Immunology (CIM) of Havana, who already appreciate to use the same principle of the drug in the treatment of oncological illnesses.
CIM sources explained to local media that the drug may not prevent the disease, but allows you to control advanced cancer, to generate antibodies against proteins that trigger slippage in the processes of cell proliferation.
Under the trade name of CIMAVAX-EGF, the vaccine was applied successfully to more than 1,000 patients in Cuba, where his health registration was conducted in June 2008.
The product was also already registered in Peru and is in the process of registration in other countries of the region, such as Colombia, Brazil, Paraguay, Ecuador and Argentina.
Is expected to soon enter phase of testing in China.
The Director of the project, Gisela Gonzalez, said last January that the vaccine is safe and does not cause severe effects increases the survival of the patient, with a good quality.
Cuban media underline that CIMAVAX-EGF is the first therapeutic vaccine against cancer lung progress registered in the world.
According to data from the World Health Organization, cancer is the leading cause of mortality worldwide, and the lung is one of the of greatest incidence.
In 2008, 7.6 million deaths were attributed to cancer, and it is expected that they will increase by more than 11 million in 2030. EFE
